These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25925046)

  • 1. [New perspectives in the approach to age-related macular degeneration].
    Gallego-Pinazo R; Zapata MA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():11-4. PubMed ID: 25925046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of aflibercept in routine clinical practice].
    Cabrera López F
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration.
    Mantel I; Gillies MC; Souied EH
    Surv Ophthalmol; 2018; 63(5):638-645. PubMed ID: 29476754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TYPE 2 (SUBRETINAL) NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH PURE RETICULAR PSEUDODRUSEN PHENOTYPE.
    Naysan J; Jung JJ; Dansingani KK; Balaratnasingam C; Freund KB
    Retina; 2016 Mar; 36(3):449-57. PubMed ID: 26383711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    García Layana A; Donate López J
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():1-2. PubMed ID: 25925043
    [No Abstract]   [Full Text] [Related]  

  • 7. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
    Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
    Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
    Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.
    Hanout M; Ferraz D; Ansari M; Maqsood N; Kherani S; Sepah YJ; Rajagopalan N; Ibrahim M; Do DV; Nguyen QD
    Biomed Res Int; 2013; 2013():830837. PubMed ID: 24319688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
    Ferreira A; Sagkriotis A; Olson M; Lu J; Makin C; Milnes F
    PLoS One; 2015; 10(7):e0133968. PubMed ID: 26208030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
    Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome.
    Oishi A; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Nakanishi H; Ueda-Arakawa N; Miyake M; Akagi-Kurashige Y; Hata M; Yoshikawa M; Kuroda Y; Takahashi A; Yoshimura N
    Am J Ophthalmol; 2015 May; 159(5):853-60.e1. PubMed ID: 25634529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
    Hall LB; Zebardast N; Huang JJ; Adelman RA
    J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D; Kaiser PK
    Immunotherapy; 2013 Feb; 5(2):121-30. PubMed ID: 23413903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.